CTLA4 and heart failure: Similar outcome was reported in meta-analysis of 13346 subjects, 3.1% of the subjects receiving either CTLA-4 inhibitor or PD-1/L1 inhibitor and 5.8% of the subjects receiving combination therapy reported to have heart failure.